Concepedia

Matthew R. Quail

MR

Statistics

Publications

14

Citations

665

H-Index

14

Active since

2001

Affiliations

GlaxoSmithKline (United States)(Current)

GlaxoSmithKline (United Kingdom)

South College

Matthew R. Quail is an author at GlaxoSmithKline (United States) specializing in medicine, drug discovery, and pharmacology.

Top concepts

Publications per year

2001–2016

14

Publications

14

Anaplastic lymphoma kinase activity is essential for the proliferation and survival of anaplastic large-cell lymphoma cells

Weihua Wan, Mark S. Albom, Lihui Lü et al. · Blood · 2005 · 105 citations

Discovery of Clinical Candidate CEP-37440, a Selective Inhibitor of Focal Adhesion Kinase (FAK) and Anaplastic Lymphoma Kinase (ALK)

Gregory R. Ott, Mangeng Cheng, Keith S. Learn et al. · Journal of Medicinal Chemistry · 2016 · 88 citations · Full text

, , +14

Characterization of Herpes Simplex Viruses Selected in Culture for Resistance to Penciclovir or Acyclovir

Robert T. Sarisky, Matthew R. Quail, Philip E. Clark et al. · Journal of Virology · 2001 · 70 citations · Full text

CEP-28122, a Highly Potent and Selective Orally Active Inhibitor of Anaplastic Lymphoma Kinase with Antitumor Activity in Experimental Models of Human Cancers

Mangeng Cheng, Matthew R. Quail, Diane E. Gingrich et al. · Molecular Cancer Therapeutics · 2011 · 68 citations

Discovery of a Potent Inhibitor of Anaplastic Lymphoma Kinase with in Vivo Antitumor Activity

Gregory R. Ott, Rabindranath Tripathy, Mangeng Cheng et al. · ACS Medicinal Chemistry Letters · 2010 · 49 citations · Full text

, , +18

1–5 of 14